Procarbazine-induced Genomic Toxicity in Hodgkin Lymphoma Survivors
Anna Santarsieri,Emily Mitchell,My H Pham,Rashesh Sanghvi,Janina Jablonski,Henry Lee-Six,Katherine Sturgess,Pauline Brice,Tobias F Menne,Wendy Osborne,Thomas Creasey,Kirit M Ardeshna,Joanna Baxter,Sarah Behan,Kaljit Bhuller,Stephen Booth,Nikesh D Chavda,Graham P Collins,Dominic J Culligan,Kate Cwynarski,Andrew Davies,Abigail Downing,David Dutton,Michelle Furtado,Eve Gallop-Evans,Andrew Hodson,David Hopkins,Hannah Hsu,Sunil Iyengar,Stephen G Jones,Mamatha Karanth,Kim M Linton,Oliver C Lomas,Nicolas Martinez-Calle,Abhinav Mathur,Pam McKay,Sateesh K Nagumantry,Elizabeth H Phillips,Neil Phillips,John F Rudge,Nimish K Shah,Gwyneth Stafford,Alex Sternberg,Rachel Trickey,Benjamin J Uttenthal,Natasha Wetherall,Xiao-Yin Zhang,Andrew McMillan,Nicholas Coleman,Michael R Stratton,Elisa Laurenti,Peter Borchmann,Sven Borchmann,Peter J Campbell,Raheleh Rahbari,George A Follows
DOI: https://doi.org/10.1101/2024.06.04.24308149
2024-06-06
Abstract:Background
Procarbazine-containing chemotherapy regimens associate with cytopenias and infertility, suggesting stem cell toxicity. Procarbazine in eBEACOPP (escalated dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisolone) is increasingly replaced with dacarbazine (eBEACOPDac) to reduce toxicity, although limited genomic and clinical data support this substitution.
Methods
To assess mutagenic and clinical consequences of dacarbazine-procarbazine substitutions, we compared mutational landscapes in haematopoietic stem and progenitor cells (HSPCs) from patients treated with different Hodgkin regimens and children, sperm and bowel tissue from procarbazine-treated patients. We compared efficacy and toxicity data of a multicentre eBEACOPDac-treated patient cohort, with eBEACOPP clinical trial and real-world datasets.
Results
eBEACOPP-treated patients exhibit a higher burden of point mutations, small insertions and deletions in HSPCs compared to eBEACOPDac and ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)-treated patients. Two novel mutational signatures, SBSA (SBS25-like) and SBSB were identified in HSPCs, neoplastic and normal colon from only procarbazine-treated patients. SBSB was also identified in germline DNA of three children conceived post-eBEACOPP and sperm of an eBEACOPP-treated male. The dacarbazine substitution did not appear to compromise efficacy; 3-year progression-free survival of 312 eBEACOPDac patients (93.3%; CI95=90.3-96.4%) mirrored that of 1945 HD18-trial eBEACOPP patients (93.3%; CI95=92.1-94.4%). eBEACOPDac-treated patients required fewer blood transfusions, demonstrated higher post-chemotherapy sperm concentrations, and experienced earlier resumption of menstrual periods.
Conclusions
Procarbazine induces a higher mutational burden and novel mutational signatures in eBEACOPP-treated patients and their germline DNA raising concerns for hereditary consequences. However, replacing procarbazine with dacarbazine appears to mitigate gonadal and stem cell toxicity while maintaining comparable clinical efficacy.